PFS
FDMT icon

Prospera Financial Services’s 4D Molecular Therapeutics FDMT Stock Holding History

Prospera Financial Services’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-150
Closed -$2K – 1937
2022
Q1 		$2K Buy
+150
New +$2.36K ﹤0.01% 2472

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Prospera Financial Services's FDMT Position: Q2 2022 in Review

Prospera Financial Services sold out of 4D Molecular Therapeutics (FDMT) in Q2 2022, closing a stake of 150 shares — an estimated $2K sold.

Prospera Financial Services first reported a position in FDMT in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 89 funds tracked by Wall St. Rank hold FDMT as of Q2 2022.

  • Prospera Financial Services reported no remaining 4D Molecular Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 150 4D Molecular Therapeutics shares in Q2 2022, an estimated $2K.
  • Prospera Financial Services first reported a position in 4D Molecular Therapeutics in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's 4D Molecular Therapeutics position peaked at $2K in Q1 2022.
  • 89 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.